Drug intelligence / Profile preview

A20FMDV2

Development stage
Unknown
Lead developer
GSK
Modality
Alpha Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta Emitters → Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Peptides
Administration
Intravenous
01

Overview

A20FMDV2 is a 20-amino-acid peptide (sequence: NAVPNLRGDLQVLAQKVART) derived from the VP1 coat protein of the foot-and-mouth disease virus (FMDV). It functions as a highly selective and high-affinity ligand for the epithelial-specific integrin αvβ6, a receptor that is significantly upregulated in various aggressive malignancies—including pancreatic ductal adenocarcinoma, cervical cancer, and non-small cell lung cancer—while remaining virtually absent in healthy adult tissues. Due to this specificity, A20FMDV2 is primarily developed as a targeting moiety for radiopharmaceuticals. When conjugated with chelators (such as DOTA or PCTA) and radiolabeled with isotopes like Copper-64 or Fluorine-18, it enables the non-invasive detection of αvβ6-positive tumors and metastatic lesions via positron emission tomography (PET). Modifications such as bi-terminal PEGylation are frequently employed to enhance its metabolic stability and optimize its pharmacokinetic profile for clinical use.

Other names
NAVPNLRGDLQVLAQKVARTalpha-v-beta-6-binding peptidealpha-v-beta6-binding peptidealpha-v-beta 6-binding peptide
02

Targets

αVβ6 (Integrin αVβ6)

Beyond the preview

Go deeper on A20FMDV2.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on A20FMDV2.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call